secwatch.observer — SEC 8-K summary
======================================

Issuer:     SPRUCE BIOSCIENCES, INC. (SPRB)
CIK:        0001683553
Form:       8-K
Filed at:   2026-05-13T12:05:18+00:00
Accession:  0001193125-26-220648
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spruce Biosciences Q1 net loss $12.3M; cash $54.1M (Mar 31), $107.3M (Apr 30)
-----------------------------------------------------------------------------

- Net loss of $12.3M ($8.94 per share) for Q1 2026; R&D expenses $7.6M, G&A $4.4M.
- Cash $54.1M at March 31, 2026; preliminary cash $107.3M at April 30, 2026; runway into H2 2027.
- Closed $69.0M diluted public offering in April 2026; secured up to $50M term loan from Avenue Capital (Tranche 1: $15M funded).
- BLA submission for TA-ERT (MPS IIIB) on track for Q4 2026; long-term data showed durable HS reduction and cognitive stabilization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1683553/000119312526220648/0001193125-26-220648-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1683553/000119312526220648/sprb-20260513.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-220648

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer